Stock plum­mets at Eye­Gate fol­low­ing Phase IIb flop for cataract surgery

The share price is cra­ter­ing to pen­ny­s­tock ter­ri­to­ry at Eye­Gate $EYEG, a phar­ma com­pa­ny mak­ing treat­ments for pain and in­flam­ma­tion fol­low­ing eye surgery, af­ter news …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER